4
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Endocrine and haemodynamic responses to graded dopamine infusion in essential hypertension

, , , , , & show all
Pages 371-377 | Received 14 Jul 1986, Accepted 10 Dec 1986, Published online: 17 Mar 2010

References

  • Langer S Z. Presynaptic regulation of the release of catecholamines. Pharmacol Rev 1981; 32: 337–62
  • Goldberg L I. Cardiovascular and renal actions of dopamine: Potential clinical applications. Pharmacol Rev 1972; 24: 1–29
  • Rajfer S I, Goldberg L I. Dopamine in the treatment of heart failure. Eur Heart J 1982; 3(Suppl. D)103–6
  • Carey R M. Acute dopaminergic inhibition of aldosterone secretion is independent of angiotensin II and adrenocorticotropin. J Clin Endocrinol Metab 1982; 54: 463–9
  • MacLeod R M. Regulation of prolactin secretion. Frontiers in Neuroendocrinology, L Martini, W A Ganong. Raven Press, New York 1976; 169–74
  • Sklar A H, Schrier R W. Central nervous system mediators of vasopressin release. Physiol Rev 1983; 63: 1243–80
  • Kjeldsen S E, Flaaten B, Eide I, Helgeland A, Leren P, Fønstelien E. Decreased peripheral dopaminergic activity in essential hypertension?. Scand J Clin Lab Invest 1983; 43: 15–20
  • Kjeldsen S E, Eide I, Aakesson I, Amundsen R, Eriksen I L, Leren P. Increased plasma free dopamine after treatment with atenolol and oxyprenolol in essential hypertension. Acta Med Scand 1983; 214: 367–71
  • Stumpe K O, Kolloch R, Higuchi M, Kruch F, Vetter H. Hyperprolactinemi and antihypertensive effect of bromocriptine in essential hypertension. Lancet 1977; 2: 211–4
  • Saruta T, Kawabe H, Fujimaki M, Nagahama S, Saito I, Kondon K. Prolactin, renin and catecholamines in essential hypertension. Clin Exp Hyptertens 1983; A5: 531–41
  • Os I, Kjeldsen S E, Westheim A, Aakesson I, Norman N, Enger E, Hjermann I, Eide I. Decreased central dopaminergic activity in essential hypertension?. J Hypertens, (in press)
  • Os I, Kjeldsen S E, Skjøtø J, Westheim A, Lande K, Aakesson I, Frederichsen P, Leren P, Hjermann I, Eide I K. Increased plasma vasopressin in low renin essential hypertension. Hypertension 1986; 8: 506–13
  • Cowley A W, Jr., Cushman W C, Quillen E W, Jr., Skelton M M, Langford H G. Vasopressin elevation in essential hypertension and increased responsiveness to sodium intake. Hypertension 1981; 3(Suppl. I)193–1100
  • Goldberg L I. Dopamine receptors and hypertension. Am J Med 1984; 77(4A)37–44
  • Rutlin E, Haug E, Torjesen P A. Serum thyro-trophin, prolactin and growth hormone, response to TRH during oestrogen treatment. Acta Endocrinol 1977; 84: 23–35
  • Os I, Kjeldsen S E, Aakesson I, Skjøtø J, Westheim A, Eide I, Leren P. Arteriovenous difference of plasma vasopressin in normal man and effect of posture. Acta Physiol Scand 1984; 122: 49–53
  • Kjeldsen S E, Flaaten B, Eide I, Helgeland A, Leren P. Evidence of increased peripheral catecholamine release in patients with longstanding untreated essential hypertension. Scand J Clin Lab Invest 1982; 42: 217–23
  • Sokal R R, Rolhlf F J. 6.1. Frequency distributions of continuous variables. Biometry, 2nd edn. W. H. Freeman & Co., San Francisco 1981; 99
  • Wallenstein S, Zucker C L, Fleise J L. Some statistical methods useful in circulation research. Circ Res 1980; 47: 1–9
  • Stoof J C, Kebabian J W. Two dopamine receptors: Biochemistry, physiology and pharmacology. Life Sci 1984; 35: 2281–96
  • Koons J C, Flynn J R, Long J F. Antagonist properties of phentolamine at both presynaptic α2-adrenoceptors and presynaptic dopamine receptors using field stimulated right cat atria. Eur J Pharmacol 1983; 88: 313–7
  • Sandrini M, Benelli A, Baraldi M. Dopamine receptors in the guinea-pig heart. A binding study. Life Sci 1984; 35: 1839–49
  • Kikuchi K, Miyama A, Nakao T, et al. Hemodynamic and natriuretic responses to intravenous infusion of dopamine in patients with essential hypertension. Jpn Circ J 1982; 46: 486–93
  • Levinson P D, Goldstein D S, Munson P J, Gill J R, Jr., Keiser H R. Endocrine, renal and hemodynamic response to graded dopamine infusions in normal men. J Clin Endocrinol Metab 1985; 60: 821–6
  • Orme M LE, Breckenridge A, Dollery C T. The effects of long-term administration of dopamine on renal function in hypertensive patients. Eur J Clin Pharmacol 1973; 6: 150–5
  • Lefkowitz R J, Caron M G, Stiles G L. Mechanisms of membrane-receptor regulation. N Engl J Med 1984; 310: 1570–9
  • Bertler A, Falck B, Owman C H, Rosengrenn E. The localization of monoaminergic blood brain barrier. Pharmacol Rev 1966; 18: 364–85
  • Morton J J, Connell J MC, Hughes M J, Inglis G C, Wallace E CH. The role of plasma osmolality, angiotensin and dopamine in vasopressin release in man. Clin Endocrinol 1985; 23: 129–38
  • Lightman S L, Forsling M L. Evidence of dopamine as an inhibitor of vasoprotein release in man. Clin Endocrinol 1980; 12: 39–46

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.